Integral Derivatives’s iShares Biotechnology ETF IBB Stock Holding History

Integral Derivatives’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-8,200	Closed	-$876K	–	822
2017 Q4	$876K	Buy	8,200 +4,300	+110%	+$460K	0.02%	532
2017 Q3	$434K	Sell	3,900 -28,500	-88%	-$3.05M	0.01%	774
2017 Q2	$3.35M	Buy	32,400 +1,800	+6%	+$177K	0.07%	182
2017 Q1	$2.99M	Sell	30,600 -24,600	-45%	-$2.36M	0.05%	226
2016 Q4	$4.88M	Buy	55,200 +49,200	+820%	+$4.48M	0.09%	146
2016 Q3	$579K	Sell	6,000 -4,200	-41%	-$400K	0.01%	588
2016 Q2	$875K	Buy	+10,200	New	+$915K	0.02%	450
2016 Q1	–	Sell	-2,100	Closed	-$237K	–	981
2015 Q4	$237K	Sell	2,100 -28,500	-93%	-$3.09M	0.01%	886
2015 Q3	$3.09M	Buy	30,600 +25,500	+500%	+$3.06M	0.08%	201
2015 Q2	$627K	Buy	5,100 +3,000	+143%	+$359K	0.02%	660
2015 Q1	$240K	Buy	+2,100	New	+$232K	0.01%	910

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Natixis Paris, France $28B AUM 26.79% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Integral Derivatives's IBB Position: Q1 2018 in Review

Integral Derivatives sold out of iShares Biotechnology ETF (IBB) in Q1 2018, closing a stake of 2,839 shares — an estimated $315K sold.

Integral Derivatives first reported a position in IBB in Q2 2014 and held it in 6 quarters. The position peaked at $2.31M in Q3 2017. 608 funds tracked by Wall St. Rank hold IBB as of Q1 2018.

Integral Derivatives reported no remaining iShares Biotechnology ETF position as of Q1 2018 after selling out during the quarter.
Integral Derivatives sold 2,839 iShares Biotechnology ETF shares in Q1 2018, an estimated $315K.
Integral Derivatives first reported a position in iShares Biotechnology ETF in Q2 2014 and held it in 6 quarters.
Integral Derivatives's iShares Biotechnology ETF position peaked at $2.31M in Q3 2017.
608 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2018.

Based on Integral Derivatives's 13F filing for Q1 2018, filed 19 Apr 2018.